Biotechnology (72) | Modification Agreements (72)

Browse by Company

Recent Contracts

Modification of Contract between the Company and the Department of Defense, United States of America, dated March 18, 2022 (portions of this exhibit (indicated by asterisks) have... (Immunome Inc., Filed With SEC on May 12, 2022)
Modification No. 01 to Base Agreement between Novavax, Inc. and Advanced Technology International, dated as of March 23, 2022 (NOVAVAX INC, Filed With SEC on May 10, 2022)
Modification No. 1 to Base Agreement, dated as of January 26, 2022, by and between the Registrant and Advanced Technology International (Regeneron Pharmaceuticals, Filed With SEC on May 4, 2022)
Modification No. 5 to Project Agreement, dated as of March 22, 2022, by and between the Registrant and Advanced Technology International (Regeneron Pharmaceuticals, Filed With SEC on May 4, 2022)
Modification No. 27, effective March 31, 2022, to the Solicitation/Contract/Order for Commercial Items (the CDC BioThrax Procurement Contract), effective December 8, 2016, from... (Emergent BioSolutions Inc., Filed With SEC on April 29, 2022)
Modification No. 12 to Undefinitized Project Agreement No. 01, dated December 20, 2021, between the Company and Advanced Technology International (NOVAVAX INC, Filed With SEC on March 1, 2022)
Modification No. 13 to Undefinitized Project Agreement No. 01, dated February 1, 2022, between the Company and Advanced Technology International (NOVAVAX INC, Filed With SEC on March 1, 2022)
Modification No. 26, effective November 1, 2021, to the CDC BioThrax Procurement Contract (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 1 (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)
Modification No. 4, effective, July 13, 2021 to the ACAM2000 Contract (Emergent BioSolutions Inc., Filed With SEC on February 25, 2022)